Independent roles of CGRP in cardioprotection and hemodynamic regulation in ischemic postconditioning

Guo, Zheng; Liu, Na; Chen, Lu; Zhao, Xin; Li, Mu-Rong

doi:10.1016/j.ejphar.2018.03.031

Cited by 17 publications

(15 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,3 It is a potent vasoactive peptide and has been suggested to be a cardioprotective mediator in conditions such as heart failure and ischemia. [2][3][4][5] CGRP has also been found in pulmonary afferent nerve fibers and contributes to vasodilation of pulmonary vasculature. 6 So what effect would exogenously blocking CGRP have on the outcome of acute respiratory failure?…”

Section: Roberstoncarrie@mayoedumentioning

confidence: 99%

“…It is not clear, for example, if temporary blockade of CGRP in these patients might predispose to worsening systemic hypertension, pulmonary hypertension, 5 or ischemic organ injury. 2,4,15 If a CGRP receptor antagonist is ultimately found to be helpful in reducing the severe morbidity and mortality of these critically ill patients, this might inspire numerous additional investigative opportunities. For instance, would CGRP antagonists be more effective if given early and continuously, similar to the ovine model of acute lung injury, or is it more effective as a treatment after some level of respiratory compromise has occurred?…”

Section: Accepted Articlementioning

confidence: 99%

See 1 more Smart Citation

Could CGRP Antagonists Be Helpful in the Fight Against COVID‐19?

Robertson

2020

Headache

View full text Add to dashboard Cite

Section: Roberstoncarrie@mayoedumentioning

confidence: 99%

Section: Accepted Articlementioning

confidence: 99%

Could CGRP Antagonists Be Helpful in the Fight Against COVID‐19?

Robertson

2020

Headache

View full text Add to dashboard Cite

“…CGRP is a strong vasodilator, suggesting that it is a defense against ischemia . However, vasodilation by itself would not be a sound protective strategy by the body because the reperfusion would cause oxidative damage to the endothelium and ischemic tissue . By pairing vasodilation with antioxidant defense and growth factor signaling, CGRP can protect against both ischemia and reperfusion injury.…”

Section: Neuroprotective Properties Of Cgrp Within the Brainmentioning

confidence: 96%

“…Elsewhere in the body, CGRP downregulates the production of oxidants and upregulates antioxidant enzymes . Thus, in ischemia and subsequent reperfusion, CGRP protects the heart muscle by reducing oxidative stress, maintaining mitochondrial membrane potential, and preventing apoptosis . This type of protection might occur in the brain as well.…”

Section: Neuroprotective Properties Of Cgrp Within the Brainmentioning

confidence: 99%

CGRP and Brain Functioning: Cautions for Migraine Treatment

Borkum

2019

Headache

View full text Add to dashboard Cite

Background Calcitonin gene‐related peptide has emerged as a therapeutic target in migraine. Monoclonal antibodies and small molecule receptor antagonists (gepants) directed against CGRP have been approved or are in Phase II or III clinical trials. For monitoring the long‐term safety of these drugs, it is helpful to consider the role of CGRP in brain functioning. Methods Qualitative review of the preclinical literature on CGRP in brain physiology and pathophysiology. Results Within the brain, CGRP is upregulated by stresses such as ischemia, injury, hyperthermia, and seizure, and activates neuroprotective processes. Thus, CGRP buffers intracellular calcium, triggers antiapoptotic signaling, upregulates a number of neurotrophins (including insulin‐like growth factor‐1/IGF‐1, basic fibroblast growth factor/bFGF, and nerve growth factor/NGF), reduces brain edema, and likely increases antioxidant defenses. When released outside the blood‐brain barrier, CGRP likely protects the endothelium, upregulates growth factor signaling from the endothelium to the brain parenchyma, strengthens the blood‐brain barrier, protects the immune privilege of the brain by inhibiting the movement of neutrophils and monocytes, and facilitates neurogenesis and angiogenesis at stem cell niches. Conclusions CGRP participates in a wide range of neuroprotective processes. In theory, migraineurs with comorbid brain pathology might be at increased risk from CGRP inhibition. However, the extent of compensating processes is unknown and will determine whether these risks materialize in practice.

show abstract

“…During AMI and recurrent episodes of micronecrosis in myocardium after PCI due to remote ischemia/reperfusion damage, the important role in the regulation of cardiac remodelling belongs to alarmins, which are released by necrotic myocardium and act as a powerful trigger of inflammatory cytokine synthesis [69]. Damaged and necrotic cardiac myocytes secrete wide-spectrum factors called DAMPs (Damage-Associated Molecular Patterns), such as highmobility group 1B protein (HMGB1), RNA, nucleotides, heat shock proteins (HSP), members of the S100 family, and IL-1a, which potentiate the inflammatory response, attenuate oxidative stress, act as direct cytotoxic agents, and induce thrombus formation and circulating blood cell aggregation [70]. Numerous molecules, such as HMGB1, S100 family members, are able to induce apoptosis of circulating endothelial progenitor cells and tissue residence cells via a multiligand receptor for advanced glycation end products-(RAGE-) mediated activation of endoplasmic reticulum stress pathway [71].…”

Section: Disease Markersmentioning

confidence: 99%

Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers

Berezin

2020

Disease Markers

View full text Add to dashboard Cite

The prevalence of heart failure (HF) due to cardiac remodelling after acute myocardial infarction (AMI) does not decrease regardless of implementation of new technologies supporting opening culprit coronary artery and solving of ischemia-relating stenosis with primary percutaneous coronary intervention (PCI). Numerous studies have examined the diagnostic and prognostic potencies of circulating cardiac biomarkers in acute coronary syndrome/AMI and heart failure after AMI, and even fewer have depicted the utility of biomarkers in AMI patients undergoing primary PCI. Although complete revascularization at early period of acute coronary syndrome/AMI is an established factor for improved short-term and long-term prognosis and lowered risk of cardiovascular (CV) complications, late adverse cardiac remodelling may be a major risk factor for one-year mortality and postponded heart failure manifestation after PCI with subsequent blood flow resolving in culprit coronary artery. The aim of the review was to focus an attention on circulating biomarker as a promising tool to stratify AMI patients at high risk of poor cardiac recovery and developing HF after successful PCI. The main consideration affects biomarkers of inflammation, biomechanical myocardial stress, cardiac injury and necrosis, fibrosis, endothelial dysfunction, and vascular reparation. Clinical utilities and predictive modalities of natriuretic peptides, cardiac troponins, galectin 3, soluble suppressor tumorogenicity-2, high-sensitive C-reactive protein, growth differential factor-15, midregional proadrenomedullin, noncoding RNAs, and other biomarkers for adverse cardiac remodelling are discussed in the review.

show abstract

Independent roles of CGRP in cardioprotection and hemodynamic regulation in ischemic postconditioning

Cited by 17 publications

References 37 publications

Could CGRP Antagonists Be Helpful in the Fight Against COVID‐19?

Could CGRP Antagonists Be Helpful in the Fight Against COVID‐19?

CGRP and Brain Functioning: Cautions for Migraine Treatment

Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers

Contact Info

Product

Resources

About